Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

American Journal of Psychiatry

Volumn 159, Issue 6, 2002, Pages 1029-1034

  Müller, Norbert ^a   Riedel, Michael ^a   Scheppach, Constanze ^a   Brandstätter, Bernd ^a   Sokullu, Safet ^a   Krampe, Karin ^a   Ulmschneider, Markus ^a   Engel, Rolf R ^a   Möller, Hans Jürgen ^a   Schwarz, Markus J ^a   House, Matt ^a   Su, Kuan Pin ^a   Chang, Hui Chih ^a   Shen, Winston W ^a   Agelink, Marcus W ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; IMMUNOMODULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; HUMAN; IMMUNE SYSTEM; MALE; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PYRAZOLES; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0036272768     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.6.1029     Document Type: Article

References (33)

1. Immunological states associated with schizophrenia
2. Viruses, schizophrenia, and bipolar disorder
3. Fibrin degradation products in post mortem brain tissue of schizophrenics: A possible marker for underlying inflammatory processes
4. Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders
5. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients
6. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients
7. Increases in CSF levels of interleukin2 in schizophrenia: Effects of recurrence of psychosis and medication status
8. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia
9. The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6
10. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood-stabilizers
11. Risperidone in the treatment of schizophrenia
12. Long-term treatment of schizophrenia with risperidone: An open-label, multicenter study of 386 patients
13. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
14. A rating scale for extrapyramidal side effects
15. Neurotoxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal antiinflammatory drugs (NSAIDs)
16. Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients
17. Relationship between immune and behavioral measures in schizophrenia
18. Cyclo-oxygenase-2 regulates inducible ICAM-1 and VCAM-1 expression in human vascular smooth muscle cells
19. Decreased levels of soluble intercellular adhesion molecule-1 (slCAM-1) in unmedicated and medicated schizophrenic patients
20. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia
21. Blood-CSF-barrier impairment as indicator for an immune process in schizophrenia
22. Levels of soluble adhesion molecules in schizophrenia: Relation to psychopathology
23. Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: The relationship to negative symptomatology
24. Acute onset of auditory hallucinations after initiation of celecoxib therapy
25. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis in a short-term pilot study
26. Cyclo-oxygenase-2 inhibitors: Rationale and therapeutic potential for Alzheimer's disease
27. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage
28. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neural cell death in primary cortical cell culture
29. Expression of mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids
30. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide
31. Cyclooxygenases in the central nervous system: Implications for treatment of neurological disorders
32. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus
33. Schizophrenie und Neurotransmitter-Störungen: Neue Perspektiven und therapeutische Ansätze